# Phase III Multicentre Trial of Oral Mesalazine in Patients With Mild to Moderate Ulcerative Colitis.

> **NCT06176560** · PHASE3 · UNKNOWN · sponsor: **Faes Farma, S.A.** · enrollment: 376 (estimated)

## Conditions studied

- Colitis, Ulcerative

## Interventions

- **DRUG:** Mesalazine

## Key facts

- **NCT ID:** NCT06176560
- **Lead sponsor:** Faes Farma, S.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2024-03
- **Primary completion:** 2025-08
- **Final completion:** 2025-08
- **Target enrollment:** 376 (ESTIMATED)
- **Last updated:** 2023-12-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06176560

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06176560, "Phase III Multicentre Trial of Oral Mesalazine in Patients With Mild to Moderate Ulcerative Colitis.". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT06176560. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*